Abstract

BackgroundConsidering the increasing use of polymyxins to treat infections due to multidrug resistant Gram-negative in many countries, it is important to evaluate different susceptibility testing methods to this class of antibiotic.MethodsSusceptibility of 109 carbapenem-resistant P. aeruginosa to polymyxins was tested comparing broth microdilution (reference method), disc diffusion, and Etest using the new interpretative breakpoints of Clinical and Laboratory Standards Institute.ResultsTwenty-nine percent of isolates belonged to endemic clone and thus, these strains were excluded of analysis. Among 78 strains evaluated, only one isolate was resistant to polymyxin B by the reference method (MIC: 8.0 μg/mL). Very major and major error rates of 1.2% and 11.5% were detected comparing polymyxin B disc diffusion with the broth microdilution (reference method). Agreement within 1 twofold dilution between Etest and the broth microdilution were 33% for polymyxin B and 79.5% for colistin. One major error and 48.7% minor errors were found comparing polymyxin B Etest with broth microdilution and only 6.4% minor errors with colistin. The concordance between Etest and the broth microdilution (reference method) was respectively 100% for colistin and 90% for polymyxin B.ConclusionResistance to polymyxins seems to be rare among hospital carbapenem-resistant P. aeruginosa isolates over a six-year period. Our results showed, using the new CLSI criteria, that the disc diffusion susceptibility does not report major errors (false-resistant results) for colistin. On the other hand, showed a high frequency of minor errors and 1 very major error for polymyxin B. Etest presented better results for colistin than polymyxin B. Until these results are reproduced with a large number of polymyxins-resistant P. aeruginosa isolates, susceptibility to polymyxins should be confirmed by a reference method.

Highlights

  • Considering the increasing use of polymyxins to treat infections due to multidrug resistant Gram-negative in many countries, it is important to evaluate different susceptibility testing methods to this class of antibiotic

  • The polymyxin E named colistin and polymyxin B have been used to treat several infections caused by multidrug resistant Pseudomonas aeruginosa (MDR-PA) isolates, which are resistant to aminoglycosides, cephalosporin and penicillins anti-pseudomonas, quinolones, monobactams and carbapenem [2,3]

  • A total of 109 strains of P. aeruginosa isolated from patients with bloodstream infection (BSI) over a 6-year period (1998–2003), were identified by Vitek

Read more

Summary

Introduction

Considering the increasing use of polymyxins to treat infections due to multidrug resistant Gram-negative in many countries, it is important to evaluate different susceptibility testing methods to this class of antibiotic. The polymyxin E named colistin and polymyxin B have been used to treat several infections caused by multidrug resistant Pseudomonas aeruginosa (MDR-PA) isolates, which are resistant to aminoglycosides, cephalosporin and penicillins anti-pseudomonas, quinolones, monobactams and carbapenem [2,3]. Our hospital has been using polymyxins as a therapeutic option to treat MDR-PA infection since an outbreak that occurred in 1992 [2,4,5]. Carbapenemresistance was defined as: isolates resistance to imipenem or meropenem by broth microdilution susceptibility testing. 2.1 Susceptibility test Polymyxin B and colistin sulfate powders were obtained from Sigma Chemical (St. Louis, Mo.). The other tested drugs were obtained commercially or provided by their respective manufacturers

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call